J9048 HCPCS code: Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg
J9048 is the HCPCS Level II code for injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg. In 2023 Medicare paid an average of $3.20 per service for J9048 across 9,626 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 35 per day on DME suppliers. In 2023, about 60 clinicians billed Medicare for J9048 for 78 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2023-01-01 |
| Last action effective | 2023-01-01 |
Who bills J9048 (2023)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 60 |
| Medicare beneficiaries | 78 |
| States with claims | 2 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9048, 2023–2023
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 9,626 | 78 | $4.14 | $3.20 |
States with the most J9048 services (2023)
| State | Services | Avg. paid |
|---|---|---|
| Pennsylvania | 1,680 | $3.65 |
| Missouri | 1,610 | $3.29 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 35 | Prescribing Information |
| outpatient hospital claims | 35 | Prescribing Information |
| practitioner claims | 35 | Prescribing Information |
What changed for J9048
- 2023-01-01: J9048 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9048?
J9048 is the HCPCS Level II code for injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg. Short descriptor: "Inj, bortezomib freseniuskab".
How much does Medicare pay for J9048?
In 2023, the average Medicare payment was $3.20 per service (average allowed $4.14).
Does Medicare cover J9048?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9048 can be billed per day?
35 on DME suppliers; 35 on outpatient hospital claims; 35 on practitioner claims (NCCI medically unlikely edits).
Related J90 codes
- J9000 — Injection, doxorubicin hydrochloride, 10 mg
- J9010 — Injection, alemtuzumab, 10 mg
- J9011 — Injection, datopotamab deruxtecan-dlnk, 1 mg
- J9015 — Injection, aldesleukin, per single use vial
- J9017 — Injection, arsenic trioxide, 1 mg
- J9019 — Injection, asparaginase (erwinaze), 1,000 iu
- J9020 — Injection, asparaginase, not otherwise specified, 10,000 units
- J9021 — Injection, asparaginase, recombinant, (rylaze), 0.1 mg
- J9022 — Injection, atezolizumab, 10 mg
- J9023 — Injection, avelumab, 10 mg
- J9024 — Injection, atezolizumab, 5 mg and hyaluronidase-tqjs
- J9025 — Injection, azacitidine, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9048
- Watch J9048 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9048
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.